儿科瘤学 儿科瘤学
Margaret Wong1, Nicole Leibman1
1The Schwarzman Animal Medical Center, The Cancer Institute, 510 East 62nd Street, New York, NY 10065, USA.
The Veterinary clinics of North America. Small animal practice
|September 19, 2025
概括
兽医儿科瘤学是一个研究不足的领域. 本综述涵盖了常见的狗儿科瘤,它们的行为和治疗困难,强调了对年轻动物癌症的更多研究的需要.
科学领域:
- 兽医医学 兽医医学 兽医医学
- 比较性瘤学研究
- 儿科瘤学 儿科瘤学
背景情况:
- 兽医儿科瘤学是一个新兴领域,对影响年幼动物的瘤的研究和病例报告有限.
- 一项2023年的研究表明,不到0.004%的1岁以下的狗被诊断出患有瘤.
- 常见的犬类儿科瘤包括皮肤囊细胞瘤,乳头瘤,巨细胞瘤,狂犬病,神经母细胞瘤和神经母细胞瘤.
研究的目的:
- 审查在兽医中发现的儿科瘤类型.
- 讨论这些瘤的多样化生物行为,从良性到攻击性.
- 概述与治疗动物儿科瘤相关的挑战.
主要方法:
- 关于兽医中儿科瘤现有研究和病例报告的文献综述.
- 对年轻动物的瘤类型,患病率和行为的分析.
- 综合有关当前治疗策略和挑战的信息.
主要成果:
- 狗的儿科瘤包括一系列的组织病理类型,包括囊细胞瘤,乳头瘤,巨细胞瘤,狂犬病瘤,神经母细胞瘤和神经母细胞瘤.
- 这些瘤表现出不同的临床行为,从自我限制到高度攻击性.
- 治疗方法通常是从成人瘤学中调整出来的,与儿科人口相关的特定挑战.
结论:
- 兽医儿科瘤学需要进一步的研究,因为瘤的发展和治疗在年轻动物的独特方面.
- 了解儿科瘤的特征对于提高诊断准确性和治疗结果至关重要.
- 需要进一步的研究,以解决年轻动物癌症管理的具体需求和挑战.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Metabolism
195
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
195
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Drug Distribution
254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
246
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246
The Retinoblastoma Gene
4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.7K
Drug Dosing: Infants and Children
256
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
256


